Tukysa (tucatinib) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient has unresectable or metastatic disease
• Patient has human epidermal growth factor receptor 2 (HER2)-amplified disease
• Patient’s tumor or metastases are wild-type RAS (KRAS wild-type and NRAS wild-type)
• Medication is used in combination with trastuzumab

Approval duration

1 year